Atlas Trials

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Clinical trial NCT00362635 · COMPLETED

Trial details

NCT number
NCT00362635
Sponsor
Bukwang Pharmaceutical
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis B
Start date
2006-08-01
Primary completion
2011-12-01
Enrollment
92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.